Cargando…

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel

Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoogland, Aasha I., Jayani, Reena V., Collier, Aaron, Irizarry‐Arroyo, Nathaly, Rodriguez, Yvelise, Jain, Michael D., Booth‐Jones, Margaret, Hyland, Kelly A., James, Brian W., Barata, Anna, Bachmeier, Christina A., Chavez, Julio C., Khimani, Farhad, Krivenko, Gabriel S., Lazaryan, Aleksandr, Liu, Hien D., Nishihori, Taiga, Pinilla‐Ibarz, Javier, Shah, Bijal D., Abidi, Muneer, Locke, Frederick L., Jim, Heather S. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957158/
https://www.ncbi.nlm.nih.gov/pubmed/33641257
http://dx.doi.org/10.1002/cam4.3664
_version_ 1783664594871386112
author Hoogland, Aasha I.
Jayani, Reena V.
Collier, Aaron
Irizarry‐Arroyo, Nathaly
Rodriguez, Yvelise
Jain, Michael D.
Booth‐Jones, Margaret
Hyland, Kelly A.
James, Brian W.
Barata, Anna
Bachmeier, Christina A.
Chavez, Julio C.
Khimani, Farhad
Krivenko, Gabriel S.
Lazaryan, Aleksandr
Liu, Hien D.
Nishihori, Taiga
Pinilla‐Ibarz, Javier
Shah, Bijal D.
Abidi, Muneer
Locke, Frederick L.
Jim, Heather S. L.
author_facet Hoogland, Aasha I.
Jayani, Reena V.
Collier, Aaron
Irizarry‐Arroyo, Nathaly
Rodriguez, Yvelise
Jain, Michael D.
Booth‐Jones, Margaret
Hyland, Kelly A.
James, Brian W.
Barata, Anna
Bachmeier, Christina A.
Chavez, Julio C.
Khimani, Farhad
Krivenko, Gabriel S.
Lazaryan, Aleksandr
Liu, Hien D.
Nishihori, Taiga
Pinilla‐Ibarz, Javier
Shah, Bijal D.
Abidi, Muneer
Locke, Frederick L.
Jim, Heather S. L.
author_sort Hoogland, Aasha I.
collection PubMed
description Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treatment. Hematologic cancer patients treated with axi‐cel (N = 103, mean age = 61, 39% female) completed SF‐36 or PROMIS‐29 QOL questionnaires prior to treatment and 90 days after. PRO‐Common Terminology Criteria for Adverse Events toxicity items were completed by patients at baseline and 14, 30, 60, and 90 days after treatment. Mixed models examined change in PROs over time. From preinfusion to 90 days later, patients reported improvements in physical functioning, pain, and fatigue (ps < 0.01), but worsening of anxiety (p = 0.02). Patient‐reported toxicities worsened by day 14 with improvement thereafter. The five most severe symptoms at day 14 included fatigue, decreased appetite, dry mouth, diarrhea frequency, and problems with concentration. Results indicate improvement in some domains of QOL over time with transient patient‐reported toxicities.
format Online
Article
Text
id pubmed-7957158
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79571582021-03-19 Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel Hoogland, Aasha I. Jayani, Reena V. Collier, Aaron Irizarry‐Arroyo, Nathaly Rodriguez, Yvelise Jain, Michael D. Booth‐Jones, Margaret Hyland, Kelly A. James, Brian W. Barata, Anna Bachmeier, Christina A. Chavez, Julio C. Khimani, Farhad Krivenko, Gabriel S. Lazaryan, Aleksandr Liu, Hien D. Nishihori, Taiga Pinilla‐Ibarz, Javier Shah, Bijal D. Abidi, Muneer Locke, Frederick L. Jim, Heather S. L. Cancer Med Clinical Cancer Research Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treatment. Hematologic cancer patients treated with axi‐cel (N = 103, mean age = 61, 39% female) completed SF‐36 or PROMIS‐29 QOL questionnaires prior to treatment and 90 days after. PRO‐Common Terminology Criteria for Adverse Events toxicity items were completed by patients at baseline and 14, 30, 60, and 90 days after treatment. Mixed models examined change in PROs over time. From preinfusion to 90 days later, patients reported improvements in physical functioning, pain, and fatigue (ps < 0.01), but worsening of anxiety (p = 0.02). Patient‐reported toxicities worsened by day 14 with improvement thereafter. The five most severe symptoms at day 14 included fatigue, decreased appetite, dry mouth, diarrhea frequency, and problems with concentration. Results indicate improvement in some domains of QOL over time with transient patient‐reported toxicities. John Wiley and Sons Inc. 2021-02-28 /pmc/articles/PMC7957158/ /pubmed/33641257 http://dx.doi.org/10.1002/cam4.3664 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Hoogland, Aasha I.
Jayani, Reena V.
Collier, Aaron
Irizarry‐Arroyo, Nathaly
Rodriguez, Yvelise
Jain, Michael D.
Booth‐Jones, Margaret
Hyland, Kelly A.
James, Brian W.
Barata, Anna
Bachmeier, Christina A.
Chavez, Julio C.
Khimani, Farhad
Krivenko, Gabriel S.
Lazaryan, Aleksandr
Liu, Hien D.
Nishihori, Taiga
Pinilla‐Ibarz, Javier
Shah, Bijal D.
Abidi, Muneer
Locke, Frederick L.
Jim, Heather S. L.
Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
title Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
title_full Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
title_fullStr Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
title_full_unstemmed Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
title_short Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
title_sort acute patient‐reported outcomes in b‐cell malignancies treated with axicabtagene ciloleucel
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957158/
https://www.ncbi.nlm.nih.gov/pubmed/33641257
http://dx.doi.org/10.1002/cam4.3664
work_keys_str_mv AT hooglandaashai acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT jayanireenav acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT collieraaron acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT irizarryarroyonathaly acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT rodriguezyvelise acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT jainmichaeld acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT boothjonesmargaret acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT hylandkellya acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT jamesbrianw acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT barataanna acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT bachmeierchristinaa acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT chavezjulioc acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT khimanifarhad acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT krivenkogabriels acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT lazaryanaleksandr acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT liuhiend acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT nishihoritaiga acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT pinillaibarzjavier acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT shahbijald acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT abidimuneer acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT lockefrederickl acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel
AT jimheathersl acutepatientreportedoutcomesinbcellmalignanciestreatedwithaxicabtageneciloleucel